Trial
NCT05669352
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
University of Florida
Collaborators
Merck Sharp & Dohme LLC
Condition
Melanoma Metastatic in the Brain
Intervention
CA-4948
Why stopped
uncertain study staffing
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-04